āĻšā§āĻŽIPN âĸ EPA
add
Ipsen SA
ā§§ā§§ā§Ž.ā§Ēā§ĻâŦ
ā§§ā§Š āĻāĻžāĻ¨ā§, ā§§ā§¨:ā§Ēā§Ļ:ā§Šā§Ļ PM GMT +ā§§ · EUR · EPA · āĻĄāĻŋāĻ¸āĻā§āĻ˛ā§āĻŽāĻžāĻ°
āĻāĻžāĻ˛ āĻļā§āĻˇ āĻ¯ā§ āĻĻāĻžāĻŽā§ āĻāĻŋāĻ˛
ā§§ā§§ā§Ž.ā§ā§ĻâŦ
āĻ¸āĻžāĻ°āĻž āĻĻāĻŋāĻ¨ā§āĻ° āĻā§āĻ°ā§āĻĄāĻŋāĻā§ā§ āĻ¸ā§āĻāĻā§āĻ° āĻĻāĻžāĻŽā§āĻ° āĻāĻ āĻž āĻ¨āĻžāĻŽāĻžāĻ° āĻ°ā§āĻā§āĻ
ā§§ā§§ā§.ā§¯ā§ĻâŦ - ā§§ā§§ā§¯.ā§Ŧā§ĻâŦ
āĻ¸āĻžāĻ°āĻž āĻŦāĻāĻ°ā§āĻ° āĻ°ā§āĻā§āĻ
ā§¯ā§¯.ā§ā§ĻâŦ - ā§§ā§¨ā§Ŧ.ā§ā§ĻâŦ
āĻŽāĻžāĻ°ā§āĻā§āĻ āĻā§āĻ¯āĻžāĻĒ
ā§¯ā§¯ā§¨.ā§Šā§Ŧ āĻā§ EUR
āĻāĻĄāĻŧ āĻāĻ˛āĻŋāĻāĻŽ
ā§Ŧā§§.ā§§ā§¨Â āĻšāĻž
P/E āĻ
āĻ¨ā§āĻĒāĻžāĻ¤
ā§§ā§Ē.ā§Ģā§Š
āĻ˛āĻā§āĻ¯āĻžāĻāĻļ āĻĒā§āĻ°āĻĻāĻžāĻ¨
ā§§.ā§Ļā§§%
āĻĒā§āĻ°āĻžāĻāĻŽāĻžāĻ°āĻŋ āĻāĻā§āĻ¸āĻā§āĻā§āĻ
EPA
āĻŦāĻžāĻāĻžāĻ° āĻ¸āĻāĻŦāĻžāĻĻ
āĻĢāĻžāĻāĻ¨āĻžāĻ¨ā§āĻ¸āĻŋā§āĻžāĻ˛ āĻĒāĻžāĻ°āĻĢāĻ°ā§āĻŽā§āĻ¯āĻžāĻ¨ā§āĻ¸
āĻā§ā§āĻ° āĻ¸ā§āĻā§āĻāĻŽā§āĻ¨ā§āĻ
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ
(EUR) | āĻā§āĻ¨ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
---|---|---|
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | ā§Žā§.ā§Ģā§¯Â āĻā§ | ā§.ā§¯ā§Š% |
āĻŦā§āĻ¯āĻŦāĻ¸āĻž āĻāĻžāĻ˛āĻžāĻ¨ā§āĻ° āĻāĻ°āĻ | ā§Ģā§Ģ.ā§ā§Ļ āĻā§ | ā§Ž.ā§Šā§§% |
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | ā§§ā§§.ā§Ŧā§Ļ āĻā§ | ā§§ā§Ž.ā§Žā§Ģ% |
āĻ¨ā§āĻ āĻĒā§āĻ°āĻĢāĻŋāĻ āĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ | ā§§ā§Š.ā§¨ā§Ē | ā§§ā§Ļ.ā§Ļā§Ŧ% |
āĻļā§ā§āĻžāĻ° āĻĒā§āĻ°āĻ¤āĻŋ āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | â | â |
EBITDA | ā§¨ā§Ē.ā§Ļā§ŽÂ āĻā§ | ā§Ļ.ā§Šā§§% |
āĻĒā§āĻ°āĻ¯ā§āĻā§āĻ¯ āĻā§āĻ¯āĻžāĻā§āĻ¸ā§āĻ° āĻšāĻžāĻ° | ā§§ā§Ŧ.ā§Šā§Ļ% | â |
āĻŦā§āĻ¯āĻžāĻ˛ā§āĻ¨ā§āĻ¸ āĻļāĻŋāĻ
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
(EUR) | āĻā§āĻ¨ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
---|---|---|
āĻā§āĻ¯āĻžāĻļ āĻ āĻāĻŽ āĻ¸āĻŽā§ā§āĻ° āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ | ā§Ēā§Ž.ā§Ģā§Ē āĻā§ | ā§§ā§.ā§Ēā§¨% |
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ | ā§Ŧā§Ģā§Ē.ā§ā§¨Â āĻā§ | ā§.ā§Ģā§Ļ% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§¨ā§Ģā§Ļ.ā§§ā§§Â āĻā§ | -ā§Ŧ.ā§¯ā§Š% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§Ēā§Ļā§Ē.ā§Ŧā§§Â āĻā§ | â |
āĻāĻāĻāĻ¸ā§āĻā§āĻ¯āĻžāĻ¨ā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāĻ° | ā§Ž.ā§¨ā§¯Â āĻā§ | â |
āĻĒā§āĻ°āĻžāĻāĻ¸ āĻā§ āĻŦā§āĻ āĻ°ā§āĻļāĻŋāĻ | ā§¨.ā§Ēā§Š | â |
āĻ¸āĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | ā§Ŧ.ā§§ā§Š% | â |
āĻŽā§āĻ˛āĻ§āĻ¨ āĻĨā§āĻā§ āĻā§ | ā§Ž.ā§Žā§Ģ% | â |
āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨
(EUR) | āĻā§āĻ¨ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
---|---|---|
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | ā§§ā§§.ā§Ŧā§Ļ āĻā§ | ā§§ā§Ž.ā§Žā§Ģ% |
āĻ
āĻĒāĻžāĻ°ā§āĻļāĻ¨ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āĻ¯āĻžāĻļ | ā§¨ā§Š.ā§Šā§Ļ āĻā§ | ā§Ž.ā§Ģā§¨% |
āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | -ā§¯.ā§¯ā§Ŧ āĻā§ | ā§ā§¯.ā§Žā§§% |
āĻĢāĻžāĻāĻ¨ā§āĻ¯āĻžāĻ¨ā§āĻ¸āĻŋāĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | -ā§§ā§Ģ.ā§¯ā§§Â āĻā§ | -ā§Ģā§§.ā§Ēā§Ģ% |
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ | -ā§¨.ā§Ŧā§Ļ āĻā§ | ā§¯ā§Š.ā§§ā§Ļ% |
āĻĢā§āĻ°āĻŋ āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§ | ā§§.ā§Ģā§Ļ āĻā§ | -ā§Žā§¯.ā§ā§Ž% |
āĻ¸āĻŽā§āĻĒāĻ°ā§āĻā§
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
āĻ¸āĻŋāĻāĻ
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāĻ¤ āĻšā§ā§āĻā§
ā§§ā§¯ā§¨ā§¯
āĻā§ā§āĻŦāĻ¸āĻžāĻāĻ
āĻāĻ°ā§āĻŽāĻāĻžāĻ°ā§
ā§Ģ,ā§Šā§¨ā§Ģ